Skull bone marrow drives immunotolerance in pediatric brain tumors
New research reveals a skull bone marrow–tumor immune axis in childhood brain cancers: CSF-borne signals educate skull hematopoietic stem and progenitor cells to present tumor antigens via MHC-II, polarizing CD4+ T cells toward regulatory T cells and promoting immunotolerance. Disrupting this axis—by normalizing CSF cytokines, mobilizing skull hematopoiesis, or blocking GM-CSF signaling with mavrilimumab (and even more so when combined with immune checkpoint blockade)—induces tumor regression in mouse models of ZFTA–RELA ependymoma, choroid plexus carcinoma, and group 3 medulloblastoma. The findings identify a skull-tumor immunological interface and suggest targeting local skull hematopoiesis as a potentially less-toxic therapy for aggressive pediatric brain tumors.